Cantor Fitzgerald Initiates Coverage on Organogenesis (NASDAQ:ORGO)

Equities researchers at Cantor Fitzgerald assumed coverage on shares of Organogenesis (NASDAQ:ORGOGet Free Report) in a research note issued to investors on Wednesday, Briefing.com reports. The brokerage set an “overweight” rating and a $5.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 45.77% from the stock’s previous close.

ORGO has been the subject of a number of other research reports. BTIG Research upped their price objective on Organogenesis from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, December 27th. Morgan Stanley upped their price objective on Organogenesis from $3.00 to $3.50 and gave the stock an “equal weight” rating in a research note on Tuesday, November 14th.

View Our Latest Stock Analysis on ORGO

Organogenesis Stock Performance

NASDAQ:ORGO opened at $3.43 on Wednesday. The stock has a 50-day simple moving average of $3.61 and a two-hundred day simple moving average of $3.07. Organogenesis has a 52-week low of $1.79 and a 52-week high of $4.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.43 and a current ratio of 2.77. The firm has a market capitalization of $452.90 million, a PE ratio of 34.30 and a beta of 1.59.

Organogenesis (NASDAQ:ORGOGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.01. Organogenesis had a return on equity of 4.83% and a net margin of 2.90%. The business had revenue of $108.53 million during the quarter, compared to analyst estimates of $112.75 million. Analysts forecast that Organogenesis will post 0.04 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Albert Erani sold 197,921 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $4.37, for a total value of $864,914.77. Following the sale, the insider now directly owns 59,025,106 shares in the company, valued at $257,939,713.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 34.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can raised its position in Organogenesis by 8.7% during the first quarter. Bank of Montreal Can now owns 21,517 shares of the company’s stock valued at $165,000 after purchasing an additional 1,721 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Organogenesis by 80.1% in the first quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after buying an additional 2,396 shares during the period. Yousif Capital Management LLC raised its holdings in shares of Organogenesis by 3.5% in the first quarter. Yousif Capital Management LLC now owns 74,492 shares of the company’s stock worth $568,000 after buying an additional 2,495 shares during the period. Credit Suisse AG raised its holdings in shares of Organogenesis by 3.7% in the second quarter. Credit Suisse AG now owns 92,961 shares of the company’s stock worth $454,000 after buying an additional 3,330 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Organogenesis by 2.4% in the fourth quarter. Legal & General Group Plc now owns 167,959 shares of the company’s stock worth $452,000 after buying an additional 3,903 shares during the period. 39.48% of the stock is currently owned by hedge funds and other institutional investors.

About Organogenesis

(Get Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.

Featured Stories

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.